Invega Sustenna

The US Food and Drug Administration approved Invega Sustenna extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults on Friday, July 31, 2009. It is the first once-monthly, long-acting, injectable atypical antipsychotic approved in the US for this use.

Sign In to MM&M

SIGN IN WITH ONE OF YOUR SOCIAL ACCOUNTS

OR

Sign in with your MM&M account

Keep me signed in Forgot your password?

Don't have one of these accounts?

Create an account for free »

Register for free with MM&M

REGISTER FOR FREE WITH ONE OF YOUR SOCIAL ACCOUNTS

OR

REGISTER FOR FREE WITH A MM&M ACCOUNT

Registration acknowledges the Terms and Conditions and Privacy Policy

Already have an account?

Log in now »

FORGET YOUR PASSWORD?

Enter your MM&M registration email address to receive a password reset link.

NEW PASSWORD SENT

Already have an account?

Log in now »

ALMOST DONE

Almost Done

Please confirm the information BELOW before Signing In

By registering you agree with our Terms and Conditions and Privacy Policy.

« CANCEL AND GO BACK